echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > CR Shuanghe and Cr Sanjiu terminate restructuring at the same time

    CR Shuanghe and Cr Sanjiu terminate restructuring at the same time

    • Last Update: 2014-05-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: the chain reaction caused by Song Lin, chairman of China Resources Group, falling down on May 6, 2014 in Shanghai Securities News gradually appeared Last night, Cr double crane and Cr 39 announced the termination of restructuring at the same time According to the reporter, the integration of China Resources pharmaceutical assets was previously decided by song Lin According to the recent changes in internal and external conditions, the controlling shareholders decided to terminate the planning of this major asset restructuring And promised not to plan for restructuring within three months As for the termination of the restructuring of China Resources Shuanghe and China Resources Sanjiu, an investment banker told Shanghai stock exchange that Song Lin was the first in charge of the restructuring of China Resources Group's pharmaceutical assets, which directly led to the transformation of the integration and restructuring process of the two companies In the future, based on the idea of stable development, Cr Shuanghe will still serve as the chemical medicine platform of Cr, Cr Sanjiu will be the traditional Chinese medicine platform, and the two companies will continue to develop according to the original idea (before planning this restructuring) Looking back at the announcement, on April 8 of this year, China Resources Sanjiu (China Resources Shuanghe also suspended trading due to the undisclosed major issues) announced the planning of major asset restructuring on April 15, and repeatedly disclosed the progress announcement On the evening of April 17, Song Lin, chairman and Secretary of the Party committee of China Resources Group, was suspected of serious violations of discipline and law, and is currently under investigation On April 19, it was decided to remove Song Lin from his leading position In this regard, the suspension of China Resources 39 once said in the announcement that Song Lin's investigation "at present" has no impact on the company's major asset restructuring However, at that time, some people in the investment circle pointed out that the restructuring of China Resources Group's pharmaceutical assets might be "in vain" Because the major restructuring of China Resources pharmaceutical is almost decided by song Lin Previously, according to the Shanghai Stock Exchange, the original plan of China Resources was to use China Resources 39 as a medical asset platform to integrate China Resources double crane into China Resources 39 However, it is understood that there are doubts about the merger within CR Shuanghe (Shanghai Securities News) related reports: a person close to China Resources Group told reporters that he was not surprised by the result of the termination of the restructuring of the pharmaceutical assets of China Resources He thought it was probably related to the investigation of Song Lin, former chairman of China Resources Group China Resources Group plans to restructure its pharmaceutical assets less than a month ago or its former chairman Song Lin is investigated and ultimately aborted On May 5, China Resources Shuanghe, a listed company of China Resources Group, took the lead in releasing the announcement on termination of planning for major asset restructuring and stock resumption According to the recent changes in internal and external conditions, the controlling shareholders are studying the asset restructuring plan and are not expected to determine the asset restructuring plan in the short term In order to protect the interests of all shareholders of the company and maintain the stability of the market, after careful consideration, it is decided to terminate the planning of this major asset restructuring In addition, Huarun Shuanghe said that according to the relevant provisions, the controlling shareholders promised not to plan the above-mentioned major asset restructuring within 3 months from the date of the announcement of termination of major asset restructuring A reporter from Securities Daily called Zhou Hui, the Secretary of the board of China Resources 39 (market bar trading point), for the first time, and said that an announcement would be released in the evening of that day However, she declined to disclose the reasons for the termination of the restructuring, saying that the announcement shall prevail A person close to China Resources Group told reporters that it was not an accident that the restructuring of the pharmaceutical assets of China Resources was terminated The person believed that it was probably related to the investigation of Song Lin, former chairman of China Resources Group At the same time, another listed company of China Resources Group, China Resources Wandong (market share bar trading point), is also in the phase of asset restructuring and trading suspension China Resources intends to sell its shares in China Resources Wandong Will the asset restructuring of China Resources Wandong also be affected? Chen Jian, a secretary of Yuyue medical (market share bar trading point), who intends to acquire the equity of China Resources Wandong, said, "this is an enterprise behavior, not an individual behavior, and everything is advancing normally." Asset restructuring of China Resources pharmaceutical: failed in less than one month, April 9 China Resources Sanjiu and China Resources Shuanghe, two of China Resources Group's subsidiaries that are expected to be restructured, issued a notice of suspension, saying that after receiving the notice from the controlling shareholder, China Resources pharmaceutical Holding Co., Ltd., China Resources pharmaceutical Holding Co., Ltd and its shareholder, China Resources Pharmaceutical Group Co., Ltd are planning major matters involving the two companies, and the suspension of trading is due to the uncertainty of relevant matters At that time, the market had a lot of speculation about the reorganization Some people believed that the reorganization plan of Cr might be to merge CR Sanjiu and Cr Shuanghe into a listing platform, inject Zizhu pharmaceutical and Secco pharmaceutical into the listed companies, and realize the integration of Cr pharmaceutical industry In addition, there are commercial sectors of China Resources pharmaceutical not listed In this regard, the above people close to China Resources Group have told reporters that China Resources Group intends to go public collectively But just when China Resources planned to restructure and go public as a whole, Song Lin, chairman of China Resources Group, was once again reported by his real name as "suspected of corruption" It is understood that this is Song Lin's second real name report Last year, he was reported to have "committed serious dereliction of duty in the process of China Resources's acquisition of Shanxi Jinye assets, resulting in a huge loss of state-owned assets" At the critical moment when the important assets of the group were restructured, the chairman of the group was twice reported by his real name, which added another cloud to the sensitive China Resources Group On April 29, Cr Shuanghe and Cr Sanjiu also announced that "relevant parties are actively studying and demonstrating major asset restructuring plans as planned, and have started relevant due diligence, audit and other work As the relevant procedures are in progress, and there is still uncertainty in relevant matters, the company's shares will continue to be suspended in order to avoid abnormal fluctuations in the company's share price and effectively safeguard the interests of investors " But this reorganization from the beginning to the end of less than a month, declared failure On May 5, Cr Shuanghe and Cr Sanjiu announced that "the controlling shareholders are studying the asset restructuring plan according to the recent changes in internal and external conditions, and it is expected that the asset restructuring plan cannot be determined in the short term After careful consideration, it is decided to terminate the planning of this major asset restructuring " The normal promotion of the sale of China Resources Wandong, which is in the suspension stage together with China Resources Shuanghe and China Resources Sanjiu, is also in the critical moment of asset restructuring On March 4, China Resources announced its strategic exit from China Resources Wandong According to the announcement of China Resources Wandong, the actual controller of the company, China Resources Corporation, plans to strategically withdraw from the medical device business Therefore, BeiYao group, the controlling shareholder of the company, plans to transfer 111 million shares of the company (accounting for 51.51% of the company's total share capital) by means of Open solicitation At the same time, China Resources pharmaceutical investment Co., Ltd., a subsidiary of China Resources, intends to transfer its 100% equity of Shanghai Medical Devices (Group) Co., Ltd through the Shanghai United Property Rights Exchange On March 5, Yuyue medical, the same medical device industry, immediately announced that it would accept the offer However, after the announcement of Yuyue medical and the resumption of trading on April 24, the stock price in the secondary market fell for two consecutive trading days But Yuyue medical care has a special interest in purchasing China Resources Wandong, and it is sure to win On April 26, China Resources Wandong released the first quarter report of 2014 Data shows that from January to March, the operating revenue of China Resources Wandong was 86.74 million yuan, a sharp decline of 30.63% The net profit attributable to the shareholders of the listed company was 14.66 million yuan, compared with 1.49 million yuan in the same period last year, 1081% year on year As for the reason for the large loss of profits, China Resources Wandong explained that "the decrease of revenue leads to the decrease of gross profit, while the increase of sales expenses and R & D expenses" Such achievements have made market investors more disappointed In the process of promoting the above-mentioned events, the investigation of Song Lin, former chairman of China Resources, aroused the high attention of the market The failure of the restructuring of China Resources Shuanghe and China Resources Sanjiu also put pressure on the same brother company, China Resources Wandong, during the critical period of asset restructuring However, Chen Jian, Secretary of the board of directors of Yuyue medical, was relatively optimistic about the matter, saying that it was a corporate action, not an individual action, and that the company's acquisition of China Resources Wandong shares was still in progress (Securities Daily)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.